- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00343187
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
A Phase II, Randomized, Double-Blind, Parallel Design Study to Evaluate ACZONE™ (Dapsone) Gel, 5% As a Treatment For Rash Related to the Human Epidermal Growth Factor Receptor 1 (HER1)/Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor Tarceva® (Erlotinib)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a randomized, double-blind, parallel design study in subjects treated with Tarceva for non-small cell lung cancer (NSCLC) who subsequently develop a rash suspected to be related to Tarceva. Only subjects who are not glucose-6-phosphate dehydrogenase (G6PD) deficient, and who have locally advanced or metastatic NSCLC and have failed at least 1 prior chemotherapy regimen indicated for Tarceva treatment will be included. Subjects will be screened and consented for the study within 3 days of initiating Tarceva therapy and will be instructed to contact the Investigator immediately when signs or symptoms of rash appear on the face. Subjects will be enrolled into the study only if a rash develops on the face and it has been confirmed and evaluated against eligibility criteria for the study.
Once enrolled, subjects will be randomly assigned to apply either ACZONE or placebo to the rash-affected areas of the face. Subjects will apply ACZONE / placebo treatment for 8 weeks, even if symptoms of the rash resolve completely. Specific efficacy assessments will include lesion counts, plaque area, erythema assessment, and pruritus assessment. Rash characteristics will be monitored using National Cancer Institute (NCI) Common Terminology Criteria Adverse Event (CTCAE) version 3.0 terms and severity descriptions and percentage of facial surface area (FSA) affected. Investigators will evaluate the subject's overall response to treatment according to a standardized multiple choice question. Throughout the study, photographs of the face will be taken.
Safety will be followed for 10 weeks (8 weeks of therapy + 2 weeks of follow-up) by monitoring adverse events, concomitant medications, and chemistry and hematology parameters. Plasma dapsone and N-acetyl dapsone concentrations will be measured to determine systemic exposure to the study treatment. Steady state plasma concentrations of erlotinib will also be measured before and after initiating the study treatment to determine any potential effects of ACZONE on pharmacokinetics of Tarceva.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611-2941
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be eligible for the study, subjects must fulfill all of the following criteria:
- Be male or female ≥18 years of age (inclusive).
- Have been prescribed Tarceva as a single agent to treat locally advanced or metastatic NSCLC, after failing at least 1 prior chemotherapy regimen.
Present with acute signs and symptoms of rash on the face that meet the following criteria:
- Are suspected to be related to Tarceva,
- Include at least 3 inflammatory lesions, and
- Are less than CTCAE Grade 3 in severity.
- Have an Eastern Co-operative Oncology Group (ECOG) performance status ≤2 and a life expectancy of at least 4 months.
- Sign an approved informed consent form for the study.
- Be willing to comply with the protocol.
Exclusion Criteria:
Subjects meeting any of the following criteria will be excluded from the study:
- A skin examination reveals the presence of another skin disease and/or condition (excessive facial hair, excessive scarring, sunburn, or other disfigurement) located on the face that, in the study physician's opinion, would confound the evaluation of the rash.
- A diagnosis of G6PD deficiency, defined as having a G6PD value below the lower limit of normal.
- A diagnosis of anemia, defined as hemoglobin <9.5 g/dL.
- Undergoing any current therapy for NSCLC other than Tarceva.
- Prior treatment with Iressa, Erbitux, or any experimental HER1/EGFR inhibitor.
- Treatment with topical antibiotics, topical steroids, and other topical treatments on the face within 14 days of Day 0 (start of ACZONE/placebo study treatment).
- Treatment with any systemic antibiotics within 7 days of Day 0 (start of ACZONE/placebo study treatment).
- Treatment with any systemic medication or therapy known to affect anti-inflammatory responses within 30 days prior to Day 0 (start of ACZONE/placebo study treatment). These medications include, but are not limited to, oral corticosteroids, cyclosporine, and methotrexate. Short-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs) before the study for non-rash related conditions is acceptable, provided that exposure is limited to ≤7 days per course. Chronic low-dose aspirin use is also acceptable.
- Active participation in an experimental therapy study or received experimental therapy within 30 days of Day 0 (start of ACZONE/placebo study treatment).
- A history of hypersensitivity to dapsone, sulfamethoxazole, trimethoprim, parabens, or any component of ACZONE.
- A poor medical risk because of other systemic diseases or active uncontrolled infections.
- Women who: are lactating; have a positive pregnancy test at Day 0, or; if sexually active and menstruating, are not practicing an adequate method of birth control. Acceptable methods of birth control include intrauterine device (IUD); oral, dermal ("patch"), implanted or injected contraceptives; tubal ligation or hysterectomy (medical documentation required); and/or barrier methods with spermicide. A surgically sterile partner is not considered an adequate method of birth control.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety: Adverse events; laboratory parameters; Vital signs; Pharmacokinetics
|
Secondary Outcome Measures
Outcome Measure |
---|
Efficacy: Lesion counts; Plaque area; % of FSA affected; Erythema Score; Pruritus VAS Score; CTCAE v3.0 Grade for rash; Proportion of subjects who have rash on the face that worsens to specific category.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Steven Garrett, MS, DDS, QLT USA, Inc
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Dapsone
Other Study ID Numbers
- ACZ EGFR 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rash
-
Rabin Medical CenterCompleted
-
Spectrum Pharmaceuticals, IncCompletedEGFR Inhibitor-associated RashUnited States, Canada
-
TWi Biotechnology, Inc.CompletedEGFR Inhibitor-Induced Skin RashTaiwan
-
National Institute of Allergy and Infectious Diseases...TerminatedSouthern Tick-Associated Rash IllnessUnited States
-
Shanghai East HospitalActive, not recruitingAcneiform EruptionsChina
-
Northwestern UniversityBayerTerminated
-
Vyne Therapeutics Inc.CompletedRash Due to Epidermal Growth Factor Receptor InhibitorsIsrael
-
McGill University Health Centre/Research Institute...Terminated
-
West Virginia UniversityTerminated
-
Hadassah Medical OrganizationCompletedRash Due to Epidermal Growth Factor Receptor Inhibitors
Clinical Trials on ACZONE (dapsone) Gel, 5%
-
AllerganCompletedRosaceaUnited States
-
Vanderbilt University Medical CenterTerminated
-
AllerganCompleted
-
AllerganWithdrawn
-
Torrent Pharmaceuticals LimitedCatawba ResearchCompletedAcne VulgarisUnited States, Belize
-
AllerganCompleted
-
Taro Pharmaceuticals USACompleted
-
Bausch Health Americas, Inc.CompletedAcne VulgarisUnited States
-
AllerganCompletedAcne VulgarisUnited States
-
John H. Stroger HospitalUnknown